Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor.
CUP
FDG-PET/CT
lymph node metastasis
unknown primary tumor
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
27 Aug 2022
27 Aug 2022
Historique:
received:
17
06
2022
revised:
22
08
2022
accepted:
25
08
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
Neoplasms in the head and neck region possess higher glycolytic activity than normal tissue, showing increased glucose metabolism. F-18-Flourodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) can identify an unknown primary tumor (CUP). The aim of this study was to assess the real-life performance of F-18-FDG-PET/CT in detecting primary sites in patients with cervical lymph node metastasis of CUP. A retrospective data analysis of 31 patients who received FDG-PET/CT between June 2009 and March 2015 in a CUP context with histologically confirmed cervical lymph node metastasis was included. In 48% of the patients (15/31), PET/CT showed suspicious tracer accumulation. In 52% of the patients (16/31), there was no suspicious radiotracer uptake, which was confirmed by the lack of identification of any primary tumor in 10 cases until the end of follow-up. FDG-PET/CT had a sensitivity of 67%, specificity of 91%, PPV of 92%, and NPV of 63% in detecting the primary tumor. Additionally, PET/CT showed suspicious tracer accumulation according to further metastasis in 32% of the patients (10/31). FDG-PET/CT imaging is a useful technique for primary tumor detection in patients in a cervical CUP context. Furthermore, it provides information on the ulterior metastasis of the disease.
Sections du résumé
BACKGROUND
BACKGROUND
Neoplasms in the head and neck region possess higher glycolytic activity than normal tissue, showing increased glucose metabolism. F-18-Flourodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) can identify an unknown primary tumor (CUP).
AIM
OBJECTIVE
The aim of this study was to assess the real-life performance of F-18-FDG-PET/CT in detecting primary sites in patients with cervical lymph node metastasis of CUP.
METHODS
METHODS
A retrospective data analysis of 31 patients who received FDG-PET/CT between June 2009 and March 2015 in a CUP context with histologically confirmed cervical lymph node metastasis was included.
RESULTS
RESULTS
In 48% of the patients (15/31), PET/CT showed suspicious tracer accumulation. In 52% of the patients (16/31), there was no suspicious radiotracer uptake, which was confirmed by the lack of identification of any primary tumor in 10 cases until the end of follow-up. FDG-PET/CT had a sensitivity of 67%, specificity of 91%, PPV of 92%, and NPV of 63% in detecting the primary tumor. Additionally, PET/CT showed suspicious tracer accumulation according to further metastasis in 32% of the patients (10/31).
CONCLUSION
CONCLUSIONS
FDG-PET/CT imaging is a useful technique for primary tumor detection in patients in a cervical CUP context. Furthermore, it provides information on the ulterior metastasis of the disease.
Identifiants
pubmed: 36140197
pii: biomedicines10092095
doi: 10.3390/biomedicines10092095
pmc: PMC9495705
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
HNO. 2017 Jun;65(6):504-513
pubmed: 28451717
Acta Otorhinolaryngol Ital. 2013 Feb;33(1):1-8
pubmed: 23620633
Eur Radiol. 2009 Mar;19(3):731-44
pubmed: 18925401
Oral Oncol. 2019 Jan;88:145-152
pubmed: 30616785
Cancer. 2004 Dec 1;101(11):2641-9
pubmed: 15517576
Head Neck. 2008 Apr;30(4):471-8
pubmed: 18023031
Eur Arch Otorhinolaryngol. 2010 Nov;267(11):1785-92
pubmed: 20814690
Nucl Med Commun. 2014 Feb;35(2):123-34
pubmed: 24220055
Eur J Nucl Med Mol Imaging. 2009 Jun;36(6):919-27
pubmed: 19205699
Cancer Imaging. 2016 Nov 4;16(1):38
pubmed: 27814768
Neoplasma. 2021 Jan;68(1):180-189
pubmed: 32880466
Oral Oncol. 2011 Jul;47(7):560-5
pubmed: 21621450
Medicine (Baltimore). 2017 Apr;96(16):e6713
pubmed: 28422888
J Natl Cancer Inst. 2008 May 21;100(10):712-20
pubmed: 18477804
Surg Oncol Clin N Am. 2015 Jul;24(3):379-96
pubmed: 25979389
Oral Oncol. 2008 May;44(5):504-8
pubmed: 17826307
Radiology. 2005 Jan;234(1):227-34
pubmed: 15564390
Head Neck. 2011 Nov;33(11):1569-75
pubmed: 21990221
Acta Radiol. 2007 Dec;48(10):1101-8
pubmed: 17963088
Clin Oncol (R Coll Radiol). 2012 Apr;24(3):190-5
pubmed: 22183080
JAMA. 2003 Dec 24;290(24):3199-206
pubmed: 14693872
Eur Arch Otorhinolaryngol. 2006 Jan;263(1):37-42
pubmed: 16003553
Oral Oncol. 2009 Mar;45(3):218-24
pubmed: 18804404
Radiology. 2015 Mar;274(3):764-71
pubmed: 25405771
Eur Arch Otorhinolaryngol. 2017 Jun;274(6):2557-2566
pubmed: 28314959
Int J Cancer. 2008 Nov 15;123(10):2390-6
pubmed: 18729183
Radiologe. 2020 Nov;60(11):1047-1051
pubmed: 33025132
Radiat Oncol. 2020 Apr 15;15(1):80
pubmed: 32293497